In a 21-year-old asymptomatic female with a family history of venous thromboembolism, which inherited and acquired thrombophilia tests beyond Factor V Leiden—including prothrombin G20210A mutation, antithrombin III, protein C, protein S, Factor X deficiency, and antiphospholipid antibodies—should be ordered?

Thrombophilia Testing for a 21-Year-Old Asymptomatic Female with Family History of Blood Clots

For a 21-year-old asymptomatic woman with a family history of VTE, testing is suggested only if she is contemplating pregnancy or estrogen use (oral contraceptives or hormone replacement therapy) AND has a first-degree relative with VTE who is known to be homozygous for Factor V Leiden or a double heterozygote for Factor V Leiden and Prothrombin G20210A. 1

Key Testing Recommendations Based on 2025 ACMG Guidelines

The most recent 2025 ACMG guidelines 1 provide clear direction that routine thrombophilia screening is NOT recommended for asymptomatic individuals with only a family history of blood clots. Testing in asymptomatic people should be highly selective and targeted.

When Testing IS Suggested for Asymptomatic Individuals:

• Siblings of individuals known to be homozygous for Factor V Leiden or Prothrombin G20210A 1
• Asymptomatic individuals contemplating pregnancy or estrogen use (oral contraceptives/HRT) who have a first-degree relative with VTE AND that relative is known to be homozygous for Factor V Leiden or double heterozygote 1

What Should Be Tested (If Testing Is Indicated):

The 2025 guidelines emphasize that *Factor V Leiden and Prothrombin G20210A (Factor II c.97G>A) are the primary genetic tests recommended 1. Beyond these:

Other inherited thrombophilias that contribute to VTE risk include:

• Antithrombin III deficiency (most quantifiable association with VTE) 1
• Protein C deficiency (more quantifiable association with VTE) 1
• Protein S deficiency (more quantifiable association with VTE) 1

These three natural anticoagulant deficiencies are tested via protein function or antigen level assays, not genetic testing 1. They account for approximately 5-10% of patients with thrombosis 1.

Regarding Factor X and Antiphospholipid Antibodies:

Factor X deficiency: The guidelines do NOT recommend routine testing for Factor X deficiency in the context of inherited thrombophilia screening. Factor X deficiency typically causes bleeding disorders, not thrombosis, so it is not part of standard thrombophilia evaluation.

Antiphospholipid antibodies: While antiphospholipid syndrome (APS) is an acquired thrombophilia that significantly impacts management 2, the 2025 ACMG guidelines focus on inherited thrombophilias. However, antiphospholipid antibodies should be considered in comprehensive thrombophilia evaluation 3, 4, particularly because:

• APS is associated with both arterial and venous thrombosis 2
• It requires different anticoagulation strategies (warfarin vs. DOACs) 2
• Testing includes lupus anticoagulant and IgG/IgM antibodies against cardiolipin and β-2-glycoprotein-I 3

Critical Caveats for Your Patient:

Testing is generally NOT recommended for asymptomatic minors or young adults because VTE rarely occurs before young adulthood even in homozygous states 1. The guidelines explicitly state that knowledge of genotype will neither alter clinical management nor affect prophylaxis decisions for many patients 1.

The Exception—When Testing Makes Sense:

If your 21-year-old patient is:

1. Considering starting oral contraceptives (major risk factor for VTE in young women)
2. AND has a first-degree relative with documented high-risk thrombophilia (homozygous Factor V Leiden or double heterozygote)

Then testing for Factor V Leiden and Prothrombin G20210A is suggested 1.

If Testing Reveals High-Risk Genotypes:

Knowledge of high-risk genotypes (homozygous Factor V Leiden, homozygous Prothrombin G20210A, or double heterozygotes) can influence:

• Contraceptive counseling (avoid estrogen-containing contraceptives) 1
• Awareness of circumstantial risks (extended travel, prolonged immobilization, surgery) 1
• Pregnancy-related thromboprophylaxis decisions 1

Important Pitfalls to Avoid:

Do not test protein C, protein S, or antithrombin levels while on anticoagulation or during acute thrombosis, as these will be falsely low 3. Diagnosis requires repetitive testing when not on anticoagulants to avoid misclassification 3.

Universal screening is not indicated because Factor V Leiden and Prothrombin G20210A have low penetrance, later age of onset, and lack of genotype-directed prophylaxis for most carriers 1. Known genetic factors are present in only 25% of screening populations without family history 1.

Bottom Line for This Patient:

Unless she is actively planning pregnancy or considering estrogen-containing contraceptives AND has a first-degree relative with documented high-risk thrombophilia, defer testing at this time 1. Instead, focus on counseling about modifiable VTE risk factors (smoking cessation, avoiding prolonged immobilization, maintaining healthy weight) and ensuring she understands when to seek medical attention for symptoms of DVT or pulmonary embolism.